These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 2693158

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model.
    Redding TW, Schally AV.
    Prostate; 1985; 6(3):219-32. PubMed ID: 3157927
    [Abstract] [Full Text] [Related]

  • 23. Reversible inhibition of gonadal functions by a potent gonadotropin-releasing hormone agonist in adult dog.
    Tremblay Y, Bélanger A.
    Contraception; 1984 Nov; 30(5):483-97. PubMed ID: 6394207
    [Abstract] [Full Text] [Related]

  • 24. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
    Labrie F, Dupont A, Belanger A, Lefebvre FA, Raynaud JP.
    J Pharmacol; 1983 Nov; 14 Suppl 3():117-35. PubMed ID: 6423907
    [Abstract] [Full Text] [Related]

  • 25. Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations.
    Labrie F, Dupont A, Belanger A, Lachance R, Giguere M.
    Br Med J (Clin Res Ed); 1985 Aug 10; 291(6492):369-70. PubMed ID: 3926197
    [Abstract] [Full Text] [Related]

  • 26. Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide.
    Moorjani S, Dupont A, Labrie F, Lupien PJ, Gagné C, Brun D, Giguère M, Bélanger A, Cusan L.
    J Clin Endocrinol Metab; 1988 Feb 10; 66(2):314-22. PubMed ID: 3276721
    [Abstract] [Full Text] [Related]

  • 27. New hormonal therapy in prostate cancer: combined use of a pure antiandrogen and an LHRH agonist.
    Labrie F, Dupont A, Belanger A, Lefebvre FA, Cusan L, Raynaud JP, Husson JM, Fazekas AT.
    Horm Res; 1983 Feb 10; 18(1-3):18-27. PubMed ID: 6411578
    [Abstract] [Full Text] [Related]

  • 28. Changes in plasma steroid levels after single administration of hCG or LHRH agonist analogue in dog and rat.
    Tremblay Y, Belanger A.
    J Steroid Biochem; 1985 Mar 10; 22(3):315-20. PubMed ID: 2581068
    [Abstract] [Full Text] [Related]

  • 29. New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and an antiandrogen.
    Labrie F, Dupont A, Belanger A, Lefebvre FA, Cusan L, Monfette G, Laberge JG, Emond JP, Raynaud JP, Husson JM, Fazekas AT.
    J Steroid Biochem; 1983 Jul 10; 19(1C):999-1007. PubMed ID: 6411995
    [Abstract] [Full Text] [Related]

  • 30. Luteinizing hormone-releasing hormone (LHRH) agonist restoration of age-associated decline of thymus weight, thymic LHRH receptors, and thymocyte proliferative capacity.
    Marchetti B, Guarcello V, Morale MC, Bartoloni G, Raiti F, Palumbo G, Farinella Z, Cordaro S, Scapagnini U.
    Endocrinology; 1989 Aug 10; 125(2):1037-45. PubMed ID: 2546733
    [Abstract] [Full Text] [Related]

  • 31. Additive inhibitory effects of treatment with an LHRH agonist and an antiandrogen on androgen-dependent tissues in the rat.
    Séguin C, Cusan L, Bélanger A, Kelly PA, Labrie F, Raynaud JP.
    Mol Cell Endocrinol; 1981 Jan 10; 21(1):37-41. PubMed ID: 6259002
    [Abstract] [Full Text] [Related]

  • 32. Selective inhibition of spermatogenesis in the presence of normal libido following combined treatment with an LHRH agonist and testosterone in the dog.
    Tremblay Y, Bélanger A, Lacoste D, Giasson M, Labrie F.
    Contraception; 1984 Dec 10; 30(6):585-8. PubMed ID: 6397329
    [Abstract] [Full Text] [Related]

  • 33. Normal gonadal functions and fertility after 23 months of treatment of prepubertal male and female dogs with the GnRh agonist [D-Trp6, des-Gly-NH2(10)]GnRH ethylamide.
    Lacoste D, Dubé D, Trudel C, Bélanger A, Labrie F.
    J Androl; 1989 Dec 10; 10(6):456-65. PubMed ID: 2695507
    [Abstract] [Full Text] [Related]

  • 34. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Schally AV, Redding TW.
    Proc Natl Acad Sci U S A; 1987 Oct 10; 84(20):7275-9. PubMed ID: 2890164
    [Abstract] [Full Text] [Related]

  • 35. Combination therapy with flutamide and [D-Trp6]LHRH ethylamide for stage C prostatic carcinoma.
    Dupont A, Labrie F, Giguere M, Borsanyi JP, Lacourciere Y, Bergeron N, Cusan L, Belanger A, Emond J.
    Eur J Cancer Clin Oncol; 1988 Apr 10; 24(4):659-66. PubMed ID: 3289945
    [Abstract] [Full Text] [Related]

  • 36. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
    Furr BJ, Tucker H.
    Urology; 1996 Jan 10; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673
    [Abstract] [Full Text] [Related]

  • 37. Morphological studies of the canine pituitary luteinizing hormone (LH) cells after long-term treatment with the LH-releasing hormone (LHRH) agonist [D-Trp6]LHRH ethylamide.
    Dubé D, Pelletier G, Labrie F.
    Endocrinology; 1987 Feb 10; 120(2):589-94. PubMed ID: 3542506
    [Abstract] [Full Text] [Related]

  • 38. Effect of chronic administration of a highly potent LHRH agonist on prostate size and secretory function in geriatric dogs.
    Vickery BH, McRae GI, Bonasch H.
    Prostate; 1982 Feb 10; 3(2):123-30. PubMed ID: 6178098
    [Abstract] [Full Text] [Related]

  • 39. Combination therapy in stage C and D prostatic cancer: rationale and five year clinical experience.
    Labrie F, Dupont A, Bélanger A, Cusan L, Giguère M, Lacourcière Y, Luthy I, Bégin D, Labrie C, Simard J.
    Cancer Metastasis Rev; 1987 Feb 10; 6(4):615-36. PubMed ID: 3327635
    [Abstract] [Full Text] [Related]

  • 40. The luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6-Pro9-NEt]LHRH increased rather than lowered LH and alpha-subunit levels in a patient with an LH-secreting pituitary tumor.
    Roman SH, Goldstein M, Kourides IA, Comite F, Bardin CW, Krieger DT.
    J Clin Endocrinol Metab; 1984 Feb 10; 58(2):313-9. PubMed ID: 6198331
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.